2024

• Butenko O, Jensen SM, Fillié-Grijpma YE, Verpalen R, Verschuuren JJ, van der Maarel SM, Huijbers MG, Plomp JJ. Change of voltage-gated sodium channel repertoire in skeletal muscle of a MuSK myasthenia gravis mouse model. Eur J Neurosci. 2024 Apr 22.

• Tannemaat MR, Huijbers MG, Verschuuren JJGM. Myasthenia gravis-Pathophysiology, diagnosis, and treatment. Handb Clin Neurol. 2024;200:283-305.

2023

• Paardekooper LM, Fillié-Grijpma YE, van der Sluijs-Gelling AJ, Zlei M, van Doorn R, Vermeer MH, Paunovic M, Titulaer MJ, van der Maarel SM, van Dongen JJM, Verschuuren JJ, Huijbers MG, On behalf of the T2B consortium. Autoantibody subclass predominance is not driven by aberrant class switching or impaired B cell development. Clin. Immunol. 2023 Nov 2:109817

• Lim JL, Augustinus R, Plomp JJ, Roya-Kouchaki K, Vergoossen DLE, Fillié-Grijpma Y, Struijk J, Thomas R, Salvatori D, Steyaert C, Blanchetot C, Vanhauwaert R, Silence K, van der Maarel SM, Verschuuren JJ, Huijbers MG. Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK. Sci Rep. 2023 May 8;13(1):7478.

• Rispens T, Huijbers MG. The unique properties of IgG4 and its role in health and disease. Nat Rev Immunol. 2023 Apr 24:1-16.

• Koers J, Sciarrillo R, Derksen NIL, Vletter EM, Fillié-Grijpma YE, Raveling-Eelsing E, Graça NAG, Leijser T, Pas HH, Laura van Nijen-Vos L, Braham MVJ, Buisman AM, de Jong J, Schriek AI, Tio-Gillen AP, Teng YKO, Steenhuis M, Swaneveld FH, de Taeye SW, van Gils MJ, Verschuuren JJGM, Rutgers B, Heeringa P, Horváth B, Jacobs BC, de Leeuw K, Franssen CFM, Veyradier A, Coppo P, Gelderman KA, Marieke van Ham S, van Els CACM, van der Woude D, Huizinga R, Huijbers MG, Kuijpers TW, Toes REM, Bos NA, Rispens T; T2B Consortium. Differences in IgG autoantibody Fab glycosylation across autoimmune diseases. J Allergy Clin Immunol 2023 Jan 27;S0091-6749(23)00091-X.

2022

• Volkov M, Coppola M, Huizinga R, Eftimov F, Huizinga TWJ, van der Kooi AJ, Oosten LEM, Raaphorst J, Rispens T, Sciarrillo R, Titulaer MJ, Wieske L, Toes REM, Huijbers MGM, van Schie KA, van der Woude D; T2B Consortium. Comprehensive overview of autoantibody isotype and subclass distribution. J Allergy Clin Immunol. 2022 Nov;150(5):999-1010.

• Vergoossen DLE, Ruiter AM, Keene KR, Niks EH, Tannemaat MR, Strijbos E, Lipka AF, van der Zijde ECJ, van Tol MJD, Bakker JA, Wevers BA, Westerberg E, Borges LS, Tong OC, Richman DP, Illa I, Punga AR, Evoli A, van der Maarel SM, Verschuuren JJ, Huijbers MG. Enrichment of serum IgG4 in MuSK myasthenia gravis patients. J Neuroimmunol. 2022 Oct 7;373:577978.

• Strijbos E, van Ostaijen-ten Dam M, Vervat C, Schilham M.W., Huijbers MG, van Tol MJD, Verschuuren JJGM. The effect of immunosuppression or thymectomy on the response to tetanus revaccination in myasthenia gravis. J Neuroimmunol. 2022 Sept;Vol 370.

• Huijbers MG, Punga A, Verschuuren JJ. Antibiotic neuromuscular junction myasthenic mimetics - Authors' reply. Lancet Neurol. 2022 Aug;21(8):681.

• Plomp JJ, Huijbers MGM, Verschuuren JJGM, Borodovsky A. A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies. J Neurosci Methods. 2022 May 1;373:109551.

• Koneczny I, Tzartos J, Mané-Damas M, Yilmaz V, Huijbers MG, Lazaridis K, Höftberger R, Tüzün E, Martinez-Martinez P, Tzartos S, Leypoldt F. IgG4 Autoantibodies in Organ-Specific Autoimmunopathies: Reviewing Class Switching, Antibody-Producing Cells, and Specific Immunotherapies. Front Immunol. 2022 Mar 24;13:834342.

• Huijbers MG, Marx A, Plomp JJ, Le Panse R, Phillips WD. Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022 Feb;21(2):163-175.

2021

• Vergoossen DLE, Keo A, Mahfouz A, Huijbers MG. Timing and localization of myasthenia gravis-related gene expression. Eur J of Neurosci. 2021 Jul. 6.

• Vergoossen DLE, Plomp JJ, Gstöttner C, Fillié-Grijpma YE, Augustinus R, Verpalen R, Wuhrer M, Parren PWHI, Dominguez-Vega E, van der Maarel SM, Verschuuren JJ, Huijbers MG. Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis. Proc Natl Acad Sci U S A. 2021 Mar 30;118(13).

• Gstöttner C, Vergoossen DLE, Wuhrer M, Huijbers MG, Domínguez-Vega E. Sheathless CE-MS as a tool for monitoring exchange efficiency and stability of bispecific antibodies. Electrophoresis. 2021 Jan;42(1-2):171 -176.

2020

• Vergoossen DLE, Augustinus R, Huijbers MG. MuSK antibodies, lessons learned from poly- and monoclonality. J Autoimmun. 2020 Aug;112:102488.

2019

• Huijbers MG, Verschuuren JJGM. Editorial: Treating muscle-specific kinase myasthenia gravis from the inside out. Neurol Neuroimmunol Neuroinflamm. 2019 Dec 12;7(1). pii: e646.

• Huijbers MG, Plomp JJ, van Es IE, Fillié-Grijpma YE, Kamar-Al Majidi S, Ulrichts P, de Haard H, Hofman E, van der Maarel SM, Verschuuren JJ. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis. Exp Neurol. 2019 Jul;317:133-143.

• Huijbers MG, Vergoossen DLE, Fillié-Grijpma YE, van Es IE, Koning MT, Slot LM, Veelken H, Plomp JJ, van der Maarel SM, Verschuuren JJ. MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity. Neurol Neuroimmunol Neuroinflamm. 2019 Feb 21;6(3):e547.

2018

• Burden SJ, Huijbers MG, Remedio L. Fundamental Molecules and Mechanisms for Forming and Maintaining Neuromuscular Synapses. Int J Mol Sci. 2018 Feb 6;19(2).

• Huijbers MG, Plomp JJ, van der Maarel SM, Verschuuren JJ. IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders. Ann N Y Acad Sci. 2018 Feb;1413(1):92-103.

• Verschuuren JJGM, Plomp JJ, Burden SJ, Zhang W, Fillié-Grijpma YE, Stienstra-van Es IE, Niks EH, Losen M, van der Maarel SM, Huijbers MG. Passive transfer models of myasthenia gravis with muscle-specific kinase antibodies. Ann N Y Acad Sci. 2018 Feb;1413(1):111-118.

• Plomp JJ, Huijbers MGM, Verschuuren JJGM. Neuromuscular synapse electrophysiology in myasthenia gravis animal models. Ann N Y Acad Sci. 2018 Jan;1412(1):146-153.

2017

• Strijbos E, Huijbers MG, van Es IE, Alleman I, van Ostaijen-Ten Dam MM, Bakker J, van Zwet EW, Jol-van der Zijde CM, van Tol MD, Verschuuren JJ. A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis. Vaccine. 2017 Nov 1;35(46):6290-6296.

2016

• Koneczny I, Stevens JA, De Rosa A, Huda S, Huijbers MG, Saxena A, Maestri M, Lazaridis K, Zisimopoulou P, Tzartos S, Verschuuren J, van der Maarel SM, van Damme P, De Baets MH, Molenaar PC, Vincent A, Ricciardi R, Martinez-Martinez P, Losen M. IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients. J Autoimmun. 2016 Dec 10.

• Huijbers MG, Niks EH, Klooster R, de Visser M, Kuks JB, Veldink JH, Klarenbeek P, Van Damme P, de Baets MH, van der Maarel SM, van den Berg LH, Verschuuren JJ. Myasthenia gravis with muscle specific kinase antibodies mimicking amyotrophic lateral sclerosis. Neuromuscul Disord. 2016 Jun;26(6):350-3.

• Huijbers MG, Vink AF, Niks EH, Westhuis RH, van Zwet EW, de Meel RH, Rojas-García R, Díaz-Manera J, Kuks JB, Klooster R, Straasheijm K, Evoli A, Illa I, van der Maarel SM, Verschuuren JJ. Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity. J Neuroimmunol. 2016 Feb 15;291:82-8.

2015

• Huijbers MG, Querol LA, Niks EH, Plomp JJ, van der Maarel SM, Graus F, Dalmau J, Illa I, Verschuuren JJ. The expanding field of IgG4-mediated neurological autoimmune disorders. Eur J Neurol. 2015 Aug;22(8):1151-61.

2014

• Gallardo E, Martínez-Hernández E, Titulaer MJ, Huijbers MG, Martínez MA, Ramos A, Querol L, Díaz-Manera J, Rojas-García R, Hayworth CR, Verschuuren JJ, Balice-Gordon R, Dalmau J, Illa I. Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev. 2014 Oct;13(10):1003-7.

• Huijbers MG, Lipka AF, Plomp JJ, Niks EH, van der Maarel SM, Verschuuren JJ. Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis. J Intern Med. 2014 Jan;275(1):12-26.

2013

• Huijbers MG*, Zhang W*, Klooster R, Niks EH, Friese MB, Straasheijm KR, Thijssen PE, Vrolijk H, Plomp JJ, Vogels P, Losen M, Van der Maarel SM, Burden SJ, Verschuuren JJ. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20783-8.

• Huijbers MG*, Lipka AF*, Potman M, Hensbergen PJ, Titulaer MJ, Niks EH, van der Maarel SM, Klooster R, Verschuuren JJ. Antibodies to active zone protein ERC1 in Lambert-Eaton myasthenic syndrome. Hum Immunol. 2013 Jul;74(7):849-51.

• Verschuuren JJ, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P, Gomez AM, De Baets MH, Losen M. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev. 2013 Jul;12(9):918-23.

2012

• Plomp JJ, Huijbers MG, van der Maarel SM, Verschuuren JJ. Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis. Ann N Y Acad Sci. 2012 Dec;1275:114-22.

• Klooster R*, Plomp JJ*, Huijbers MG, Niks EH, Straasheijm KR, Detmers FJ, Hermans PW, Sleijpen K, Verrips A, Losen M, Martinez-Martinez P, De Baets MH, van der Maarel SM, Verschuuren JJ. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain. 2012 Apr;135(Pt 4):1081-101.